GlassScriptPhysician profile
Ali Hussain
NPI 1003267006
$1,172.36
in general payments reported to CMS, 2019-2025
15 companies · $379 in 2025
The $379 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $37.76 · 2023: $231 · 2024: $403 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $667 · Education: $346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $666.74 |
| Education | $345.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $423.21 | 2023-2025 | Jakafi, Niktimvo, Monjuvi |
| Merck Sharp & Dohme LLC | $240.40 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $117.04 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $104.44 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $69.99 | 2024 | Soliris |
| Astrazeneca Pharmaceuticals LP | $44.15 | 2023-2024 | Imfinzi |
| Janssen Biotech, INC. | $37.66 | 2023-2025 | Darzalex, Talvey, Imbruvica |
| Alkermes, INC. | $23.38 | 2024 | Aristada, Lybalvi |
| Sumitomo Pharma America, INC. | $20.04 | 2025 | Orgovyx |
| Abbvie INC. | $18.87 | 2024 | |
| Array Biopharma INC | $16.41 | 2024 | Mektovi, Braftovi, Tukysa |
| Philips North America LLC | $16.31 | 2019 | |
| Adc Therapeutics America, INC. | $14.73 | 2023 | |
| Redhill Biopharma INC. | $13.46 | 2020 | |
| Allergan, INC. | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Hussain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.